Cochlear share price surges 6% on solid half and buyback

cochlear share price

cochlear share priceThe Cochlear Limited (ASX: COH) share price is charging higher on Wednesday.

In early trade, the hearing solutions company’s shares are up over 6% to $222.87.

Investors have been bidding the Cochlear share price higher following the release of the company’s half year results.

Cochlear share price higher on strong result

  • Sales revenue up 9% to $893 million
  • Statutory net profit down 16% to $142 million
  • Underlying net profit down 10% to $142 million
  • Interim dividend maintained at $1.55 per share
  • On-market share buy-back announced
  • Guidance reaffirmed

What happened during the half?

For the six months ended 31 December, Cochlear reported a 9% increase in sales revenue to a record of $893 million. This was driven by strong growth in cochlear and acoustic implant revenue.

Cochlear implant units increased 14% over the prior corresponding thanks partly to strong demand for the Cochlear Nucleus 8 Sound Processor, which was launched during the second quarter. This was supported by the continuing recovery from COVID surgery delays across the emerging markets.

Things weren’t quite as positive for Cochlear’s earnings, at least on paper. Its statutory net profit was down 16% to $142 million due to one-off gains included in the prior corresponding period.

On an underlying basis, its net profit was down 10%. This reflects an increase in cloud computing‐ related expenses, new product launch costs, and the impact of the weighting in operating expenses to the second half of FY 2022.

Excluding its cloud computing‐related expenses, Cochlear’s underlying profit margin would have been 17%, which is just a touch below its long term target of 18%.

Despite this profit decline and thanks to the strength of its balance sheet, the Cochlear board has maintained its interim dividend at $1.55 per share.

Speaking of balance sheet strength, management has announced a progressive on-market share buy-back this morning. This will start with a $75 million buy-back, after which the company intends to progressively buy shares over the coming years until its cash balance is approximately $200 million.

Cochlear finished the period with a cash balance of $505 million, though $170 million will be used for an impending acquisition.


Cochlear has reaffirmed its guidance for the remainder of the financial year.

It is expecting underlying net profit in the range of $290 million to $305 million, which will be a 5% to 10% increase on FY 2022’s underlying net profit or an increase of 8% to 13% when adjusted for the increase in cloud computing‐related expenses.

Commenting on trading conditions, management said:

Trading conditions have been progressively improving, in line with expectations, with intermittent COVID‐related hospital or region‐specific elective surgery restrictions or staffing shortages continuing. While surgical and clinical capacity to serve implant candidates appears to have stabilised, we continue to be mindful of the pressure on the healthcare system globally to contend with surgical waiting lists, ongoing staffing challenges and growing demand. We will continue our investment in R&D and market growth activities to support long‐term market growth.

The post Cochlear share price surges 6% on solid half and buyback appeared first on The Motley Fool Australia.

Should you invest $1,000 in Cochlear Limited right now?

Before you consider Cochlear Limited, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear Limited wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of February 1 2023

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];[property] = defaultValue;

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s